FDA Approves Merck's Lipfendra Cholesterol Pill
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA approved Merck's once-daily pill Lipfendra, a first-of-its-kind treatment designed to lower LDL cholesterol beyond what statins alone can achieve.
- Clinical studies showed Lipfendra reduced LDL cholesterol by up to 60% over six months in adults with or at risk for atherosclerotic cardiovascular disease.
- Analysts expect Lipfendra to generate peak annual sales exceeding $5 billion.
- Separately, Kalshi — one of the world's largest prediction market exchanges — announced plans to take bets on clinical trial outcomes and FDA regulatory approvals, partnering with AppliedXL to monitor and predict study results.
- Kalshi will initially restrict markets to Phase 3 trial outcomes run by established drug companies and full FDA approval decisions.
Why it matters: Merck's Lipfendra enters a market where analysts project peak annual sales exceeding $5 billion, offering high-cholesterol patients a statin alternative that reduced LDL by up to 60% in six-month trials. Kalshi's launch of clinical trial betting markets brings prediction-market wagering to Phase 3 outcomes from established drug companies.
